Ann: 2015 AGM - Chairman's Address and CEO Presentation, page-11

Noticing buyers coming back into the stock because they realise the potential of CLV.

The positives on CLV from the Chairman's address:

"The company is developing market opportunities in Europe and the
Americas. Peter is leaving tomorrow for Europe for two weeks
to meet existing and potential new customers";

"The Company’s balance sheet remains in a strong position with
cash reserves providing support for the ongoing operations and
further investment to grow the business in the future";

"The strengthening of the sales force with the appointment of two
senior sales professionals responsible for maximising existing
markets and the development of new markets. This focus and
emphasis on new customers is already bearing fruit as Australian
and New Zealand infant formula manufacturers gain access to
the Chinese market through licensing agreements with
distributors";

Premneo Update:
–The Major phase 3 clinical trial for respiratory health has recruited 1273
babies and will be completed by December 2015 with results issued Q2 2016
–Patents for respiratory and neurological development have been awarded in
Australia and the USA
– Clover Sub-licenced its Preterm product to Premneo Pharmaceuticals
Limited in October 2015
– Premneo is headed by Dr. Brian McNamee previous CEO of CSL, who has
proven experience, a strong team and the capability to drive the successful
launch of our pharmaceutical product​